<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2809">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417257</url>
  </required_header>
  <id_info>
    <org_study_id>LAU-20-01</org_study_id>
    <nct_id>NCT04417257</nct_id>
  </id_info>
  <brief_title>Study of LAU-7b for the Treatment of COVID-19 Disease in Adults</brief_title>
  <acronym>RESOLUTION</acronym>
  <official_title>RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laurent Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laurent Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled Phase 2 Study of LAU-7b against confirmed&#xD;
      COVID-19 Disease in hospitalized patients at a higher risk of complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESOLUTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2 study of&#xD;
      LAU-7b for the treatment of COVID-19 Disease in patients at a higher risk than the general&#xD;
      COVID-19 Disease population to develop complications while hospitalized.&#xD;
&#xD;
      The goal of the study is to evaluate the efficacy of LAU-7b therapy + standard-of-care&#xD;
      relative to placebo + standard-of-care in patients with COVID-19 Disease with confirmed&#xD;
      SARS-CoV-2 infection.&#xD;
&#xD;
      The purpose of the treatment with LAU-7b is to prevent the worsening of the health of&#xD;
      hospitalized patients including aggravation such as recourse to mechanical ventilation and&#xD;
      death.&#xD;
&#xD;
      The means are the direct effects of LAU-7b on the resolution of inflammation, interference&#xD;
      with viral proliferation and protection from excessive pro-inflammatory response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, parallel groups and placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be randomly assigned to take either the active drug (LAU-7b capsule) or a matching inactive placebo (inactive capsule)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive and free of respiratory failure (Ordinal Scale scores 1-4)</measure>
    <time_frame>On Day 29</time_frame>
    <description>This will be assessed through health status scoring using the World Health Organization 7-point Ordinal Scale, a higher score is worse than a low score.&#xD;
Not hospitalized, no limitations on activities;&#xD;
Not hospitalized, limitation on activities;&#xD;
Hospitalized, not requiring supplemental oxygen;&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or extra-corporeal membrane oxygenation;&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through monitoring and probing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status of the patient on the 7-point Ordinal Scale compared to placebo</measure>
    <time_frame>On Days 14 and 29</time_frame>
    <description>This will be assessed through health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-causes death, depicted by a change from baseline in the Ordinal Scale score to category 7</measure>
    <time_frame>On Days 29 and 60</time_frame>
    <description>This will be assessed through Day 60 health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an improvement of one category on the ordinal scale patient health status, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death, defined here as a time to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>This will be assessed through daily health status scoring using the World Health Organization 7-point Ordinal Scale (shown with the primary outcome measure), a higher score is worse than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization (days) within the study period Days 1-29, compared to placebo</measure>
    <time_frame>From baseline to Day 60</time_frame>
    <description>Monitoring of the hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo</measure>
    <time_frame>On Days 1, 5, 8, 12 and 14</time_frame>
    <description>This will be assessed through serial oropharyngeal swabs for SARS-CoV-2 viral detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey</measure>
    <time_frame>On Days 1, 14, 29, 45 and 60</time_frame>
    <description>This will be assessed through questionnaire filling, in person or remotely</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>COVID-19 Disease</condition>
  <arm_group>
    <arm_group_label>LAU-7b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug as LAU-7b capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule (as inactive capsules identical to active arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAU-7b</intervention_name>
    <description>LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.</description>
    <arm_group_label>LAU-7b</arm_group_label>
    <other_name>fenretinide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must exhibit symptoms of COVID-19 disease at screening;&#xD;
&#xD;
          2. Subjects must be 18 years and older, of either gender;&#xD;
&#xD;
          3. Subjects must have at least one of the following factors/co-morbidities:&#xD;
&#xD;
               1. Controlled or uncontrolled diabetes;&#xD;
&#xD;
               2. Pre-existing cardiovascular disease, including hypertension;&#xD;
&#xD;
               3. Pre-existing respiratory disease such as COPD, asthma, emphysema;&#xD;
&#xD;
               4. Active smoker with a 20 pack-years of smoking;&#xD;
&#xD;
               5. Obesity as depicted by body mass index ≥ 30;&#xD;
&#xD;
               6. Laboratory tests indicative of a higher risk of COVID-19-related complications,&#xD;
                  such as troponin &gt;1.5 upper limit of normal and/or CRP &gt;1.5 upper limit of normal&#xD;
&#xD;
               7. Patient aged 70 years and older who, based on the judgment of the Investigator,&#xD;
                  is at a higher risk of developing complications.&#xD;
&#xD;
          4. Subjects must have a documented positive test for the SARS-CoV-2 virus or be suspected&#xD;
             to be positive and with a test result pending;&#xD;
&#xD;
          5. Subjects must be under observation by, or admitted to a controlled facility or&#xD;
             hospital to receive standard-of-care for COVID-19 disease;&#xD;
&#xD;
          6. Subject's health status must be 3, 4 or 5 on the ordinal scale, and not previously a&#xD;
             6;&#xD;
&#xD;
          7. If female, must be either post-menopausal (one year or greater without menses),&#xD;
             surgically sterile, or, for female subjects of child-bearing potential who are capable&#xD;
             of conception, must be: practicing a highly effective method of birth control&#xD;
             (acceptable methods include intrauterine device, complete abstinence, spermicide +&#xD;
             barrier, male partner surgical sterilization, or hormonal contraception) during the&#xD;
             study and through 30 days after the last dose of the study medication. Periodical&#xD;
             abstinence is not classified as an effective method of birth control. A pregnancy test&#xD;
             must be negative at the Screening Visit;&#xD;
&#xD;
          8. Subjects must have the ability to understand and give informed consent, which can be&#xD;
             verbal with a witness, according to local requirements;&#xD;
&#xD;
          9. Subjects deemed capable of adequate compliance including attending scheduled visits&#xD;
             for the duration of the study;&#xD;
&#xD;
         10. Subjects must be able to swallow the study drug capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding;&#xD;
&#xD;
          2. Health condition deemed to possibly interfere with the study endpoints and/or the&#xD;
             safety of the patients. For example, the following conditions should be considered&#xD;
             contraindicated for participation in the study, but this is not an exhaustive list. In&#xD;
             case of doubt, the Investigator should consult with the sponsor's medical&#xD;
             representative:&#xD;
&#xD;
               1. Presence of inherited retinitis pigmentosa;&#xD;
&#xD;
               2. Presence or history of liver failure;&#xD;
&#xD;
               3. Presence or history of stage 4 severe chronic kidney disease or dialysis&#xD;
                  requirement;&#xD;
&#xD;
               4. Febrile neutropenia;&#xD;
&#xD;
               5. Presence of active cancer treated with systemic chemotherapy or radiotherapy.&#xD;
&#xD;
          3. Known history of a severe allergy or sensitivity to retinoids, or with known allergies&#xD;
             to excipients in the oral capsule formulation proposed to be used in the study;&#xD;
&#xD;
          4. Participation in another drug clinical trial within 30 days (or a minimum of 5&#xD;
             elimination half-lives) prior to screening, except ongoing participation in&#xD;
             non-interventional studies;&#xD;
&#xD;
          5. Calculated creatinine clearance (CrCL, using the Cockroft-Gault equation for example)&#xD;
             &lt;60 ml/min.&#xD;
&#xD;
          6. Presence of total bilirubin &gt;1.5 x ULN (in the absence of demonstrated Gilbert's&#xD;
             syndrome), ALT and/or AST &gt; 2.5 x ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramy Saleh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marie Houle, PhD</last_name>
    <phone>514-941-2313</phone>
    <email>jmhoule@laurentpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radu Pislariu, MD</last_name>
    <phone>514-513-2252</phone>
    <email>rpislariu@laurentpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chandler Regional Medical Center / Mercy Gilbert Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annette Taylor, RN BsN CCRC</last_name>
      <phone>480-728-5721</phone>
    </contact>
    <contact_backup>
      <last_name>Jennine Zumbuhl, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Brian Tiffany, MD PhD FACEP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center Beaches</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine M Richmond</last_name>
    </contact>
    <investigator>
      <last_name>Jennifer C Fulton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Lukes Hospital</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejla Godusevic, BSc</last_name>
      <phone>208-381-4717</phone>
    </contact>
    <contact_backup>
      <last_name>Dixie Durham, MHS RRT</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karen S Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Sprenger, RN BS</last_name>
      <phone>319-353-8862</phone>
    </contact>
    <investigator>
      <last_name>Alejandro Comellas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center, 2001 Medical Parkway, Belcher Pavillion</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaci Miller</last_name>
      <phone>443-481-5738</phone>
    </contact>
    <investigator>
      <last_name>Barry R Meisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University, Harper University Hospital and Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cahill, RN APN-C</last_name>
      <phone>313-745-9537</phone>
    </contact>
    <contact_backup>
      <last_name>Debra M Driscoll, RN</last_name>
      <phone>313-745-2221</phone>
    </contact_backup>
    <investigator>
      <last_name>Zubin Mukadam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Horne</last_name>
      <phone>843-402-0227</phone>
    </contact>
    <investigator>
      <last_name>Kent J. Stock, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Whipple, RN</last_name>
      <phone>713-441-3247</phone>
    </contact>
    <investigator>
      <last_name>Faisal Zahiruddin, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges Youssef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy-Lisa Gagné</last_name>
      <phone>418-541-1000</phone>
      <phone_ext>2707</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Vanessa Larouche</last_name>
      <phone>418-541-1000</phone>
      <phone_ext>3064</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Christian Allard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSSS de l'Est-de-l'Ile-de-Montréal, Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danae Tassy, PhD</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>4679</phone_ext>
    </contact>
    <investigator>
      <last_name>François Marquis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Beaudoin, MSc RRT</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14635</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Guillaume Coté-Maurais, MSc</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14635</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>François Tremblay, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Robitaille, PhD</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>26194</phone_ext>
    </contact>
    <investigator>
      <last_name>Andrew Hirsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmela Pepe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Agulnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Palayew, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Jagoe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Small, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lama Sakr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylene Roy</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36382</phone_ext>
    </contact>
    <investigator>
      <last_name>Ramy Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Campbell Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS Ds Laurentides</name>
      <address>
        <city>Saint-Jérôme</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Sardin Laframboise</last_name>
      <phone>450-431-1020</phone>
    </contact>
    <investigator>
      <last_name>Sébastien Poulin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Host-directed treatment</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>Pro-resolving</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

